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Abstract
Introduction: Calcium and vitamin D malabsorption in coeliac disease (CD) predispose to skeletal demineralisation. The aim of this study 
was to evaluate the prevalence of bone mineral density (BMD) and calcium deficiencies in adult patients with CD and assess whether 
a gluten-free diet is sufficiently effective for BMD restoration.
Material and methods: BMD and biochemical parameters of bone and mineral metabolism were measured in 35 adult CD patients re-
ceiving (19) or not receiving (16) a gluten-free diet (GFD) and in 36 controls. Then the CD patients were treated with a GFD and calcium 
(1.0 g/day) plus alfacalcidol (0.25–1 μg/day) for one year.
Results: Reduced BMD was diagnosed in 57–77% of the patients. Mean calcaemia, calciuria, and 25(OH) vitamin D were lower, but serum 
PTH and bone-turnover markers (ALP, osteocalcin, ICTP) were significantly higher in the CD patients than in the controls. In the patients 
on the diet (GFD(+)), BMD was higher than in the GFD(–) patients, but lower than in the controls. The biochemical parameters were 
normal in the GFD(+) patients except for diminished calciuria. Mean BMD after one year of treatment significantly increased (p < 0.05), 
mostly in the lumbar spine (mean: 7.3%), but decreased in five patients who did not strictly adhere to the GFD.
Conclusions: Deficiencies in calcium, vitamin D, and BMD are very common in adult CD patients. Gluten avoidance increased BMD, 
although the values remained markedly lower in several patients. Because of chronic calcium deficiency despite GFD, calcium and vitamin 
D supplementation in most adult CD patients is proposed. (Endokrynol Pol 2012; 63 (4): 270–276)
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Streszczenie
Wstęp: Upośledzone wchłanianie wapnia i witaminy D w przebiegu celiakii (CD) sprzyja demineralizacji szkieletu. Celem niniejszej pracy 
było zbadanie gęstości mineralnej kości (BMD) i niedoborów wapnia u dorosłych chorych na CD oraz ocena skuteczności stosowania 
diety bezglutenowej w odbudowie BMD.
Materiał i metody: Gęstość mineralną kości oraz biochemiczne wykładniki metabolizmu kostnego zmierzono u 35 dorosłych chorych na 
CD, wśród których 19 stosowało, a 16 nie stosowało diety bezglutenowej, oraz u 36 osób z grupy kontrolnej. Następnie wszystkim chorym 
na CD zalecono stosowanie diety bezglutenowej, wapnia (1 g/d.) i alfakalcydolu (0,25–1 μg/d.) przez rok.
Wyniki: Obniżoną BMD stwierdzono u 57–77% chorych na CD. Średnie kalcemia, kalciuria i stężenie witaminy 25(OH)D były u nich niż-
sze, natomiast stężenia PTH i markerów obrotu kostnego (fosfatazy alkalicznej, osteokalcyny, ICTP) były wyższe niż w grupie kontrolnej. 
U chorych na CD stosujących dietę bezglutenową (GFD(+)) BMD była wyższa niż u chorych niestosujących tej diety (GFD(–)), ale niższa 
niż u zdrowych osób. Wyniki badań biochemicznych w grupie GFD(+) były prawidłowe, pominąwszy kalciurię, która utrzymywała się 
na zmniejszonym poziomie. Po roku leczenia dietą z suplementacją wapnia i witaminy D obserwowano istotny wzrost BMD (p < 0,05), 
zwłaszcza w obrębie kręgosłupa lędźwiowego (średnio o 7,3%). U 5 chorych, którzy nie przestrzegali ściśle diety, BMD obniżyła się.
Wnioski: W przebiegu CD niedobory wapnia, witaminy D i BMD są bardzo częste. Stosowanie diety bezglutenowej poprawia BMD, 
jednak u wielu chorych pozostaje ona obniżona. Według autorów, ze względu na przewlekły niedobór wapnia, u dorosłych chorych na 
CD, oprócz diety bezglutenowej, należy stosować suplementację wapnia i witaminy D. (Endokrynol Pol 2012; 63 (4): 270–276)
Słowa kluczowe: gęstość mineralna kości, markery obrotu kostnego, celiakia, dieta bezglutenowa, hipokalcemia
Introduction
Coeliac disease (CD) is a disorder resulting from the 
exposure of predisposed individuals to some cereal 
grain proteins (gluten) and is associated histologically 
with villous atrophy of the mucosa of the small intestine. 
The diagnosis of CD is made most frequently during 
childhood, with another peak during the fourth and 
fifth decades of life. According to recent screening 
studies, coeliac disease affects about 1% of the adult 
population [1], but the prevalence of coeliac disease 
among osteoporotic individuals is much higher, from 
1.7% [2, 3] to 3.4% [4].
The diagnosis of CD may be very difficult because 
the clinical picture is highly variable and characteris-
tic intestinal symptoms may be absent. Patients with 
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coeliac disease often have osteopenia, osteomalacia, or 
osteoporosis because of calcium and vitamin D malab-
sorption and secondary hyperparathyroidism. Impaired 
absorption of calcium results principally from the loss of 
villous cells in the proximal intestine, where calcium is 
most actively absorbed, and also from unabsorbed fatty 
acids which bind calcium in the intestinal lumen and 
may reduce dietary vitamin D absorption. A gluten-free 
diet (GFD) is suspected to reverse the metabolic bone 
disease.
The aim of our study was to evaluate the prevalence 
of bone mineral density (BMD) and calcium deficien-
cies in adult patients with coeliac disease and to assess 
whether a gluten-free diet is sufficiently effective for 
BMD restoration or whether calcium and vitamin D 
supplementation should be additionally applied.
Materials and methods
The study group consisted of 35 adults with CD (six men 
and 29 premenopausal women), 41.5 ± 13.6 years old, 
with a mean BMI (body mass index) of 20.07 ± 2.53 kg/ 
/m2. The patients were selected from a group of about 
6,000 persons hospitalised during two consecutive years 
in the Departments of Endocrinology and Gastroen-
terology at Wroclaw Medical University. Nine patients 
were referred to our Endocrinology Department for 
evaluation of hypocalcaemia or low BMD without 
prior CD diagnosis, and 26 patients were recruited 
to the study from the Gastroenterology Department 
with already established coeliac disease and were on 
a gluten-free diet or were newly diagnosed.
The diagnosis of coeliac disease was based on clinical 
presentation, small-intestinal biopsy prior to treatment 
with a gluten-free diet, and clinical improvement on 
gluten withdrawal. All patients had villous atrophy in 
the proximal small bowel of grade III or IV on the basis 
of Marsh’s classification [5]. In all patients, IgA-class 
antiendomysial antibody (EMA) and tissue transglu-
taminase antibody (tTGA) were positive before treat-
ment [6]. It is very difficult to establish the mean illness 
duration because the clinical picture of CD in adults 
is highly variable and the intestinal signs may not be 
characteristic, or even completely absent. According to 
the illness history, we assumed that the mean duration 
of illness in our patients was about 16.8 ± 11.7 years 
(range: 1–44 years).
Exclusion criteria were other diseases and medications 
known to affect bone mineral density, especially vitamin D 
or mineral supplementation during the year before exami-
nation, as well as impaired renal function. Four patients 
had a history of previous bone fracture. In two cases, the 
fractures were posttraumatic (hand and lower leg), one 
patient had a low-energy fracture of the arm and another 
had compression of the thoracic spine. Most of the patients 
(65.7%) had anaemia, usually multideficiency anaemia. 
A transitory clinical manifestation of hypocalcaemia in 
the form of tetany was observed in 14 of the patients. The 
coeliac disease patients also suffered from other autoim-
mune diseases, such as Hashimoto’s disease (six persons 
with proper L-thyroxin supplementation), vitiligo (2), and 
dermatitis herpetiformis (1). At the start of the study, 19 
patients had been receiving a gluten-free diet for at least 
one year, while 16 persons did not apply it, or applied it 
inconsistently.
The control group consisted of 36 healthy volunteers 
(ten men and 26 premenopausal women), 39.1 ± 12.7 
years old, with normal BMIs (23.9 ± 3.3 kg/m2). There 
was no significant difference in age between the study 
and control groups, but the mean body mass index was 
lower in the CD patients (p < 0.001), which is typical 
of this illness.
Study protocol
Bone mineral density at the lumbar spine (L2–L4), femo-
ral neck, distal third and ultradistal sites of the forearm, 
and of the total body, was measured by dual-energy 
X-ray absorptiometry (DPX-L, Lunar, USA). T-scores (the 
number of SDs above or below the young adult mean 
BMD) and Z-scores (age-adjusted BMD) were calculated 
with reference to a local normative population BMD 
database. Osteoporosis was recognized when the BMD 
value was lower than 2.5 SD below that of a young adult 
person (T-score) according to the WHO definition. The 
in vivo precision (CV-coefficient of variation) of the 
BMD measurements were 1.48% for the lumbar spine, 
2.68% for femoral neck, 2.6% for the distal part of the 
forearm, 4.49% for the ultradistal part of the forearm and 
0.76% for the total body. LSCs (least significant changes) 
were calculated using the advanced calculator on the 
www.pfo.pl recommended by The Polish Foundation 
of Osteoporosis, according to the following formula: 
LSC = 2.77 × RMS SD (root mean square standard de-
viation) which would represent a statistical difference 
at the 95% confidence level.
Laboratory analyses
Serum and urinary solutes and alkaline phosphatase (ALP) 
were measured using standard laboratory methods. Os-
teocalcin (a bone formation indicator) was estimated by 
IRMA using a kit (OSTEO-RIACT, France). Serum intact 
parathormone was analysed using an IRMA kit (Bio- 
-Source, Europe S.A.). The bone resorption marker ICTP 
(C-terminal telopeptide of type I collagen) was exstimated 
using a RIA kit (Orion Diagnostica). 1,25-dihydroxy vita-
min D (1,25-(OH)2D3) and 25-hydroxy vitamin D (25-OH 
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After the initial examination, all the CD patients were 
obliged to follow a gluten-free diet with vitamin D ana-
logue and calcium supplementation in individual doses 
that normalised serum calcium levels, removed tetany, 
and usually lowered increased PTH level. We usually 
used 0.25–1 μg of alfacalcidol (Alfadiol, GlaxoSmithKline 
Pharmaceuticals) and 1,000 mg of elementary calcium 
daily. One year later, all the biochemical analyses and 
bone mineral density measurements were repeated.
Statistical analysis
The statistical significance of differences between 
paired data was calculated using Wilcoxon’s signed 
rank test and the Mann-Whitney U test was used to 
compare values between different sample groups. Cor-
relation coefficients were determined using Spear-
man’s rank correlation. The results are presented as 
the mean ± SD. Statistical significance was defined 
as p < 0.05.
The study was approved by the Wroclaw Medical 
University Local Ethics Committee.
Results
Bone mineral densities in the patients with coeliac dise- 
ase were significantly lower than in the controls (Table 
I). The lumbar spine appeared to be particularly affected 
(p < 0.001). Reduced BMDs were found in most patients 
with coeliac disease, as shown in Table II.
As a result of calcium deficiency in the CD patients, 
we observed slightly lower serum calcium concentra-
tions and much lower 24-hour urine calcium excretion 
compared to the control group. The 25-OH vitamin D 
serum concentration was also diminished. The mean 
PTH level was higher in the patients with CD than in 
the controls. At the time of the study, we observed PTH 
concentrations above the normal value (6.5–29.0 pg/ 
/mL) in eight patients, but 21 patients had a history 
of elevated PTH in tests performed previously. The 
serum concentrations of biochemical markers of bone 
turnover, such as ALP, osteocalcin, and ICTP, were also 
significantly higher, as presented in Table III.
Bone mineral density negatively correlated with 
patient age (p < 0.05). Age-adjusted BMD (Z-score) 
at all sites positively correlated with calcium serum 
concentration, and BMD in the lumbar spine and total 
body positively correlated with 25-OH D3 concentration 
(p < 0.05) but negatively with osteocalcin (p < 0.01). 
Negative correlations with BMD at all sites were also 
observed for parathormone and alkaline phosphatase 
(p < 0.05). Apart from BMD, parathormone negatively 
correlated with calcium and 25-OH D3 serum concen-
tration (p < 0.05) and positively correlated with such 
bone-turnover markers as osteocalcin (p < 0.001), al-
kaline phosphatase, and ICTP (p < 0.05). Bone mineral 
density and biochemical parameters in the patients 
Table I. Mean bone mineral density in patients with coeliac disease (n = 35) and in the control group (n = 36). Results are 
presented as the T-score and Z-score (mean ± SD)
Tabela I. Gęstość mineralna kości u chorych z celiakią (n = 35) i w grupie kontrolnej (n = 36). Wyniki przedstawiono jako 
T-score i Z-score (średnia ± SD)
T-score  Z-score
Coeliac disease p value Control group Coeliac disease p value Control group
Femoral neck –1.27 ± 1.27 *** 0.12 ± 0.87 –0.6 ± 1.0 ** 0.09 ± 0.65
Lumbar spine –1.47 ± 1.72 *** 0.64 ± 1.15 –0.91 ± 1.43 *** 0.73 ± 0.85
Forearm, distal –1.53 ± 1.44 * –0.55 ± 0.79 –1.37 ± 1.24 * –0.3 ± 0.83
Forearm, 
ultradistal
–2.22 ± 1.44 ** –0.68 ± 1.8 –2.11 ± 1.36 * –0.42 ± 2.08
Total body –1.99 ± 1.41 *** –0.17 ± 0.86 –1.27 ± 1.18 *** 0.18 ± 0.7
*p < 0.05, **p < 0.01, ***p < 0.001; SD — standard deviation
Table II. Frequency of decreased bone mineral density (BMD) 
in patients with coeliac disease expressed as a percentage of 
the patients (n = 35)
Tabela II. Częstość zmniejszonej gęstości mineralnej kości (BMD) 
u chorych z celiakią wyrażona jako odsetek chorych (n = 35)
Total patients with 
BMD deficiency
Osteoporosis
(T-score < –1.0) 
[%]
(T-score ≤ –2.5) 
[%]
Femoral neck 62.8 20
Lumbar spine 57.2 28.6
Forearm, distal 57 22.8
Forearm, ultradistal 77 42.8
Total body 77.1 31.4
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Table III. Serum and urine biochemistry in patients with coeliac disease and controls
Tabela III. Wyniki badań biochemicznych surowicy krwi i moczu u chorych z celiakią i w grupie kontrolnej
Parameter Coeliac disease 
N = 35
p value Control group 
N = 36
Calcaemia [mmol/L]                2.17 ± 0.22 * 2.29 ± 0.14
Calciuria [mmol/24-h] 1.80 ± 1.35 *** 4.49 ± 0.87
Phosphataemia [mmol/L] 0.98 ± 0.28 ns 1.08 ± 0.17
ALP [U/L] 260.7 ± 149.6 * 174.3 ± 47.0
PTH [pg/mL] 20.17 ± 15.0 * 12.2 ± 6.9
25-OH D3 [ng/mL] 29.9 ± 18.3 * 39.5 ± 19.0
1,25-(OH)2D3 [pg/mL] 40.08 ± 15.5 ns 36.6 ± 14.5
Osteocalcin [ng/mL] 35.31 ± 18.84 ** 23.6 ± 8.6
ICTP [μg/mL] 5.9 ± 5.06 ** 3.3 ± 1.8
*p < 0.05, **p < 0.01, ***p < 0.001; ns — not significant; ALP — alkaline phosphatase; PTH — intact parathormone; ICTP — C-terminal telopeptide 
of type I collagen; 1,25-(OH)2D3 — 1,25-dihydroxyvitamin D; 25-OH D3 — 25-hydroxyvitamin D
Table IV. Serum and urine biochemistry in patients with coeliac disease receiving or not receiving a gluten-free diet





p value Coeliac disease  
GFD (+) 
N = 19
p value Control group 
N = 36
Calcaemia [mmol/L] 2.07 ± 0.28 * 2.26 ± 0.11 ns 2.29 ± 0.14
Calciuria [mmoL/24-h] 1.13 ± 0.58 * 2.39 ± 1.5 *** 4.49 ±.0.87
ALP [U/L] 309.9 ± 137.1 * 210.5 ± 146.2 ns 174.3 ± 47.0
PTH [pg/mL] 27.3 ± 18.4 * 15.1 ± 8.5 ns 12.2 ± 6.9
25-OH D3 [ng/mL] 19.9 ± 18.8 * 37.8 ± 13.8 ns 39.5 ± 19.0
1,25-(OH)2D3 [ng/mL] 45.2 ± 17.5 ns 35.8 ± 12.7 ns 36.6 ± 14.5
Osteocalcin [ng/mL] 46.0 ± 23.6 * 26.9 ± 6.7 ns 23.6 ± 8.6
ICTP [μg/mL] 8.0 ± 6.4 * 4.3 ± 2.9 ns 3.3 ± 1.8
*p < 0.05, ***p < 0.001; ns — not significant; ALP — alkaline phosphatase; PTH — intact parathormone; ICTP — C-terminal telopeptide of type I 
collagen; 1,25-(OH)2D3 — 1,25-dihydroxyvitamin D; 25-OH D3 — 25-hydroxyvitamin D; GFD (+) — patients receiving a gluten-free diet;  
GFD (–) — patients not receiving a gluten-free diet or applying it inconsistently
who strictly followed the gluten-free diet were gener-
ally better than in the newly diagnosed patients and 
patients who did not apply the diet consistently, but 
their results were different from those of the control 
group (see Tables IV and V).
During the ensuing year, all the CD patients received 
a gluten-free diet and vitamin D and calcium supple-
mentation in individual doses that normalised serum 
calcium levels, removed tetany, and usually lowered 
increased PTH level.
After one year of the treatment, we repeated 
the BMD and serum and urine parameter measure-
ments. The mean BMD in the whole CD patient group 
after one year of treatment was significantly higher at 
all sites (p < 0.05) except for the ultradistal forearm. 
The highest increase in BMD was in the lumbar spine, 
as shown in Table VI. Unfortunately, in five patients 
we observed decreases in BMD (Figure 1). The control 
tests for tTGA were positive, indicating lax adherence 
to the gluten-free diet. There were no new fractures 
during the study.
The increases in femoral, lumbar, and total body 
BMD positively correlated with initial ICTP concentra-
tion (p < 0.01). The biochemical abnormalities were con-
siderably reduced after one year. We observed increases 
in serum calcium (p < 0.05) and 25-OH D3 (p < 0.01) 
concentrations. The 24-h calciuria level increased sig-
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Table V. Bone mineral density (BMD) in patients with coeliac disease receiving or not receiving a gluten-free diet, and in the 
control group. The results of BMD measurement are given as the Z-score (mean ± SD)
Tabela V. Gęstość mineralna kości (BMD) u chorych z celiakią stosujących dietę bezglutenową lub niestosujących tej diety 




p value Coeliac disease 
GFD (+) 
N = 19
p value Control group 
N = 36
Femoral neck –1.12 ± 0.87 * –0.23 ± 0.98 ns 0.09 ± 0.65
Lumbar spine –1.96 ± 1.1 ** –0.14 ± 1.11 ** 0.73 ± 0.85
Forearm, distal –1.56 ± 1.32 ns –1.23 ± 1.24 * –0.3 ± 0.83
Forearm, ultradistal –3.11 ± 0.98 *** –1.39 ± 1.21 ns –0.42 ± 2.08
Total body –1.96 ± 1.82 ns –0.83 ± 0.92 ** 0.18 ± 0.7
*p < 0.05, **p < 0.01, ***p < 0.001; ns — not significant; GFD (+) — patients receiving a gluten-free diet; GFD (–) — patients not receiving  
a gluten-free diet or applying it inconsistently
Table VI. Change in bone mineral density (BMD) after one-year treatment with gluten free diet, calcium, and alfacalcidol 
in coeliac disease patients (n = 35). Results are given as the percentage of the initial BMD value
Tabela VI. Zmiany gęstości mineralnej kości (BMD) po roku leczenia dietą bezglutenową, wapniem i alfakalcydolem u chorych 
z celiakią (n = 35). Wyniki przedstawiono jako odsetek wyjściowej wartości BMD
Initial BMD [g/cm2] Change in BMD [%]
Mean ± SD Mean ± SD Minimum Maximum
Femoral neck 0.84 ± 0.15 2.5 ± 6.9 –13.2 15.9
Lumbar spine 0.87 ± 0.46 7.3 ± 13.2 –11.0 35.8
Forearm, distal 0.62 ± 0.10 3.0 ± 4.3 –3.8 12.8
Forearm, ultradistal 0.30 ± 0.06 0.43 ± 12.0 –25.8 28.6
Total body 0.97 ± 0.10 1.4 ± 4.4 –6.8 9.0
but, unlike other parameters, it was still lower than in 
the control group (p < 0.05). The osteocalcin and PTH 
concentrations were significantly diminished after treat-
ment (p < 0.01 and p < 0.05, respectively).
Discussion
Reduced BMD was found in 57–77% of our patients, 
depending on the site examined. This confirms opin-
ions that coeliac disease affects bone mineral density 
in most cases [7–13]. Based on the histories of 13,000 
patients with coeliac disease, Ludvigsson et al. stated 
that individuals with coeliac disease, including children, 
may be at increased risk of hip fracture and fracture 
of any type [14]. The most important mechanism of 
BMD decline is probably initial calcium malabsorption 
[15, 16] caused by villous atrophy and, secondarily, by 
coexisting vitamin D deficiency [16–19]. This leads to 
secondary hyperparathyroidism [11, 17–22], increased 
bone resorption, and increased but inadequate bone 
formation. Increased levels of bone-turnover markers 
can be detected as evidence of enhanced bone remodel-
ling [18, 20, 23]. We observed all the above pathologies 
in most of our patients with coeliac disease. The mean 
calcaemia, calciuria, and vitamin 25-OH D3 levels in 
the CD patients were lower than in the control group, 
but parathormone, bone formation markers (alkaline 
phosphatase, osteocalcin), and bone resorption marker 
(C-terminal telopeptide of type I collagen) serum 
concentrations were significantly higher. The 1,25- 
-(OH)2 D3 level was normal or elevated in most of CD 
patients, presumably because of stimulation of renal 
25OHD-1-alpha-hydroxylase by PTH.
A gluten-free diet is essential for the treatment of coe-
liac disease and, if strictly followed, should remove the 
nutritional deficiency and reverse bone metabolic disease. 
At the start of our study, the patients receiving a gluten-free 
diet over a longer period (at least one year) had normal 
values of bone-turnover markers and other biochemical 
parameters, except for calciuria, which was lower than in 
the control group (p < 0.001). Bone mineral density values 
were significantly higher in the patients receiving than in 
those not receiving a GFD, but worse than in the control 
group. After one year of treatment with a gluten-free diet, 
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calcium, and alfacalcidol, the coeliac patients, as a group, 
increased their BMD. The individual changes were differ-
ent and the greatest improvement was by as much as 35% 
of the initial BMD value, occurring in the lumbar spine. 
However, in five patients there was a decrease in BMD, 
and the control tests for anti-tissue transglutaminase anti-
body were positive in these persons, indicating mistakes, 
probably unintentional, in adherence to the gluten-free 
diet [24, 25].
Studies performed in children with coeliac disease 
showed a marked improvement in bone density val-
ues after short-term treatment and the maintenance 
of normal BMD values after long-term treatment 
[26–28]. In adults, the frequent lack of gastrointes-
tinal symptoms in some patients delays diagnosis 
of and specific therapy for coeliac disease. Patients 
are mostly diagnosed in adulthood, after the age at 
which the maximum rate of gain in bone mass oc-
curs, and a possible explanation for the observed low 
BMD is that they failed to reach an optimal peak bone 
mass in early adulthood. This is perhaps the main 
reason for the different degrees of BMD deficiency 
and different levels of effectiveness of a gluten-free 
diet observed in adults. Many authors confess that 
although there is improvement in clinical symptoms 
and BMD with a gluten-free diet in adults, attain-
ment of normal bone density may take several years, 
and in some individuals may not occur at all [8, 22, 
29–31]. There are also suggestions that the inflamma-
tory process in active CD, which is associated with 
inflammatory cytokines release, might have a role in 
BMD deficiency [32, 33].
The 24-h calciuria level after one year of treatment in 
our CD patients increased significantly (p < 0.01), but, 
unlike other parameters, it was still lower than in the 
control group (p < 0.05), suggesting a chronic calcium 
deficiency. We propose the addition of calcium and 
vitamin D to a gluten-free diet in coeliac patients, es-
pecially as a gluten-free diet may not provide adequate 
dietary calcium due to the lack of bread and cereals. In 
addition, some CD patients are deficient in lactase and 
may avoid dairy products high in calcium to prevent 
symptoms of lactose intolerance. Adequate provision 
with calcium and vitamin D is particularly important 
in patients with an elevated PTH serum concentration 
[34], because this can stop enhanced bone resorption 
faster that diet alone. In some of our patients with high 
PTH levels at the start of the study, we were not able 
to normalise it quickly using GFD and average doses 
of calcium and vitamin D, although the parathyroid 
gland showed proper reaction on intravenous calcium 
infusion.
Conclusions
We would like to state that calcium and vitamin D de-
ficiency is very common in adult patients with coeliac 
disease. This leads to secondary hyperparathyroidism 
and low bone mineral density. A gluten-free diet im-
proves calcium and vitamin D absorption, diminishes 
secondary hyperparathyroidism, and increases BMD, 
but does not guarantee full recovery, as we observed in 
our group receiving GFD before the study. We recom-
mend calcium and vitamin D supplementation in adult 
coeliac patients, especially at the beginning of treatment. 
We suggest that bone mineral density, serum calcium, 
ALP, PTH, and daily calciuria be routinely measured in 
all coeliac disease patients. Patients with unexplained 
low BMD, hypocalcaemia, hypocalciuria, and secondary 
hyperparathyroidism should be examined for malab-
sorption and CD, even in the absence of gastrointestinal 
symptoms.
Support
This study was supported by grant no. 901 from Wroc- 
law Medical University.
Figure 1. Individual changes in bone mineral density (BMD) 
values after one-year treatment in 5 patients with lax adherence 
to the gluten-free diet; LSC — least significant change
Rycina 1. Indywidualne zmiany gęstości mineralnej kości (BMD) 
po roku leczenia u 5 chorych, którzy nie przestrzegali ściśle diety 
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